Academic Journal
Q2Clinical Colorectal Cancer
About Clinical Colorectal Cancer
About Clinical Colorectal Cancer
Clinical Colorectal Cancer is a peer-reviewed scholarly journal published by Elsevier B.V. (United States). It focuses on Q2. Publication coverage spans 2001-2026.
Key indicators: ISSN 1533-0028, 1938-0674; H-index 71.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (71): Strong citation impact — 71 articles cited at least 71 times each, reflecting solid influence.
Publishing in Clinical Colorectal Cancer
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Clinical Colorectal Cancer?
1533-0028, 1938-0674.
Who publishes Clinical Colorectal Cancer?
Elsevier B.V..
What are Clinical Colorectal Cancer's metrics?
H-index 71.
Where do I submit to Clinical Colorectal Cancer?
Via the official website.
Is Clinical Colorectal Cancer peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Colorectal Cancer Treatments and Studies; Colorectal Cancer Surgical Treatments; Colorectal and Anal Carcinomas; Gastric Cancer Management and Outcomes; Genetic factors in colorectal cancer; Cancer Treatment and Pharmacology.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,690.00 USD; 3,450.00 EUR; 2,950.00 GBP; 457,670.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line treatment in circulating tumor DNA–selected metastatic colorectal cancer (ROMANCE trial)
Alessandra Pia D’Agata, Gloria Pellizzari, Giulia Martini, Michele Ghidini et al.
2026-10 · DOI: 10.1016/j.clcc.2026.09.004Early-Onset Colorectal Cancer: Epidemiology, Etiologic Pathways, and Emerging Prevention Strategies
Amit Syal, Steven J. Cohen
2026-10 · DOI: 10.1016/j.clcc.2026.09.005A Phase I Study of Nab-Paclitaxel, Gemcitabine and AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas: ECOG-ACRIN EA2131
Jennifer R. Eads, Ju-Whei Lee, Cheng E. Chee, Neal J. Meropol et al.
2026-09 · DOI: 10.1016/j.clcc.2026.08.004Time to Double Down: Dual Immunotherapy as the Best Bet for Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer
Mir Lim, Van Morris
2026-09 · DOI: 10.1016/j.clcc.2026.07.003Detection of Polyps in Colon Capsule Endoscopy and Impact of Colonic Transit Time
Ola Selnes, Lea Østergaard Hansen, Benedicte Schelde-Olesen, Thomas Bjørsum-Meyer et al.
2026-09 · DOI: 10.1016/j.clcc.2026.04.002Discordant Dynamics Between Absolute ctDNA and Tumor Fraction During Treatment Monitoring in Metastatic Colorectal Cancer: Evidence of a Dilution Phenomenon
Yuji Takayama, Kosuke Ichida, Taro Fukui, Nao Kakizawa et al.
2026-09 · DOI: 10.1016/j.clcc.2026.05.001Diagnostic and Treatment Intervals for Colorectal Cancer and Associations With Overall Survival and Disease Stage: An Australian Data Linkage Study
Allison Drosdowsky, Karen E. Lamb, Luc te Marvelde, Peter Gibbs et al.
2026-09 · DOI: 10.1016/j.clcc.2026.08.003Application of a Domestic Chinese Robotic Surgical System in Radical Resection Combined With Lateral Lymph Node Dissection for Low Rectal Cancer: A Retrospective Study
Feng Zheng, Aihe Sun, Peng Zhai, Zhongming Bao et al.
2026-09 · DOI: 10.1016/j.clcc.2026.07.002EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis
Victor Simmet, Astrid Lièvre, Emmanuelle Samalin, Hélène Senellart et al.
2026-09 · DOI: 10.1016/j.clcc.2026.09.001Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database
Thomas Samaille, Morteza Raeisi, Romain Cohen, Qian Shi et al.
2026-09 · DOI: 10.1016/j.clcc.2026.05.007Real-world treatment and outcomes for patients with deficient mismatch repair metastatic colorectal cancer following pembrolizumab availability in Australia
Grace Kim, Vanessa Wong, Matthew Loft, Belinda Lee et al.
2026-09 · DOI: 10.1016/j.clcc.2026.09.003Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment
Salvatore Corallo, Francesco Agustoni, Anna Pagani, Francesco Serra et al.
2026-09 · DOI: 10.1016/j.clcc.2026.05.002Interobserver Agreement and Radiological–Pathological Concordance of CT Staging in Localized Colon Cancer
Giovanni Trovato, Maria Alessandra Calegari, Priscilla Testa, Silvia De Vizio et al.
2026-09 · DOI: 10.1016/j.clcc.2026.08.005Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer
Simar Gill, Ned Liu, Elaine Ngan, Rajvi J. Wani et al.
2026-09 · DOI: 10.1016/j.clcc.2026.08.006Resource Use and Costs of the Low-risk Arm of a Risk-stratified Colorectal Cancer Screening Approach Based on Previous Negative FIT Values: Comparative Analyses With the Standard Approach
Andrea Buron, Merce Comas, Carmen Guirado-Fuentes, Cristina Barrufet et al.
2026-09 · DOI: 10.1016/j.clcc.2026.05.005Editorial Board
2026-09 · DOI: 10.1016/s1533-0028(26)00060-5Liver Transplantation for Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of Survival Outcomes
Gabriel Valagni, Rafael Alvim Pereira, Gabriel Lenz, Gabriel Barcellos et al.
2026-09 · DOI: 10.1016/j.clcc.2026.09.002Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer
Lisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, David S. Hong et al.
2026-09 · DOI: 10.1016/j.clcc.2026.04.003Comparing Quality of Life in Rectal Cancer Survivors Managed With Watch-and-Wait Versus Surgery
Sina Vatandoust, Luigi Sposato, David Wattchow, John Leung et al.
2026-09 · DOI: 10.1016/j.clcc.2026.05.006Table of contents
2026-09 · DOI: 10.1016/s1533-0028(26)00061-7Reviews
Community Reviews
Version History
October 9, 2026 at 9:19 pm
October 2, 2026